Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
| ▸ | BPTF | Q12830 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28996058 | 1.00 | AR (0.48) | ARNOTUMATML3MBTL1SLC18A3 | |
| SCHEMBL30252765 | 1.00 | AR (0.48) | ARNOTUMATML3MBTL1SLC18A3 | |
| SCHEMBL31334193 | 0.90 | SMARCA2 (0.40) | ARNOTUMATML3MBTL1SLC18A3 | |
| SCHEMBL31334501 | 0.90 | SMARCA2 (0.40) | ARNOTUMATML3MBTL1SLC18A3 | |
| SCHEMBL22290739 | 0.90 | DHFR (0.44) | NOTUMATML3MBTL1SLC18A3NPY5R | |
| SCHEMBL21683097 | 0.86 | ALOX5 (0.43) | ATML3MBTL1SLC18A3NPY5R | |
| SCHEMBL1811310 | 0.81 | BPTF (0.44) | NOTUMATML3MBTL1NPY5RBPTF | |
| SCHEMBL1811312 | 0.81 | BPTF (0.44) | NOTUMATML3MBTL1NPY5RBPTF | |
| SCHEMBL21460258 | 0.80 | KHK (0.47) | NOTUMATML3MBTL1BPTFEPHX2 | |
| SCHEMBL2334802 | 0.80 | BPTF (0.61) | ARNOTUMBPTF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197375-A1 | PYRIMIDINES AND METHODS OF THEIR USE | Kineta, Inc. | 2025-06-19 | — | — | US | disclosed |
| CN-118922188-A | Pyrimidine and methods of use thereof | 奇尼塔公司 | 2024-11-08 | — | — | CN | disclosed |
| EP-4444309-A1 | PYRIMIDINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023107603-A1 | PYRIMIDINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107603-A1 | PYRIMIDINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| CN-109651358-B | 4-aminopyridine derivative, pharmaceutical composition, preparation method and application thereof | 上海迪诺医药科技有限公司 | 2023-04-07 | — | — | CN | disclosed |
| US-20210179600-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS INHIBITORS OF ASK1 | Hepagene Therapeutics (HK) Limited (HK) | 2021-06-17 | — | — | US | disclosed |
| US-20130210809-A1 | NOVEL 2-AMINO-4-PYRAZOLYL-THIAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | BOLEA CHRISTELLE (CH) | 2013-08-15 | — | — | US | disclosed |
| US-20130210809-A1 | NOVEL 2-AMINO-4-PYRAZOLYL-THIAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | BOLEA CHRISTELLE (CH) | 2013-08-15 | — | — | US | disclosed |
| US-20130210809-A1 | NOVEL 2-AMINO-4-PYRAZOLYL-THIAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | BOLEA CHRISTELLE (CH) | 2013-08-15 | — | — | US | disclosed |
| EP-2595986-A2 | NOVEL 2-AMINO-4-PYRAZOLYL-THIAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharma SA (CH) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012009009-A2 | NOVEL 2-AMINO-4-PYRAZOLYL-THIAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA S.A. (CH) | 2012-01-19 | — | — | WO | disclosed |
| US-20100056531-A1 | ALKYL-SUBSTITUTED 3' COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056531-A1 | ALKYL-SUBSTITUTED 3' COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | HTR6, HTR3B, HTR1B | AR 99/4885NOTUM 4140/4885ATM 2729/4885 |
| US-20250197375-A1 | PYRIMIDINES AND METHODS OF THEIR USE | TDP1, TYMP, TARDBP | AR 4577/4885NOTUM 3495/4885ATM 151/4885 |
| US-20210179600-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS INHIBITORS OF ASK1 | IRAK1, IRAK2, IRAK3 | AR 3876/4885NOTUM 4113/4885ATM 71/4885 |
| US-20130210809-A1 | NOVEL 2-AMINO-4-PYRAZOLYL-THIAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM2, GRM4, GRM1 | AR 1871/4885NOTUM 3617/4885ATM 3185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.